Investigating Tumoral And Temporal Heterogeneity Through Comprehensive-Omics Profiling In Patients With Metastatic Triple Negative Breast Cancer

1093Background: The “Intensive Trial of OMics in Cancer”-001 (ITOMIC-001; Clinicaltrials.gov ID: NCT01957514) enrolls patients with metastatic triple negative breast cancer (TNBC) who are platinum-naive and scheduled to receive cisplatin. Multiple biopsies (up to 7 metastatic sites) are performed under carefully controlled conditions prior to and upon completion of cisplatin treatment and following any subsequent therapies. Samples are chosen for DNA sequencing, RNA sequencing, and quantitative proteomics (GPS Cancer). Here we describe the -omic alterations acquired during treatment. Methods: We analyzed 74 biopsies from 17 patients taken at various clinical timepoints (e.g. initial diagnosis, initial trial recruitment, following cisplatin treatment, etc.) spanning 2 years on trial and over 8 years before recruitment. This dataset includes 64 whole genomes (with matched-normal blood samples), 44 RNAseq expression profiles, and 23 proteomic sets. GPS Cancer, which comprises whole genome sequencing, whole t...